Notice Pursuant to Section 708(5)(e) of the Corporations Act 2001
Imagion Biosystems gives notice that, on 20 October 2020 the Company issued 2,401,900 fully paid ordinary shares (Shares) in the Company as the result of…
IBX Secures Additional Capital — Shareholders Exercise Options
Imagion Biosystems announced that it has received a total of $143,157 for the exercise of options. Composed of $142,200 for 2,370,000 options exercisable at 6…
Imagion Biosystems Appoints Geoff Hollis as CFO
Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the…
HREC Approval for Phase I Study
Imagion Biosystems is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense® HER2 Phase I study…
Issue of Unlisted Performance Options under EIP
Imagion Biosystems today announced "Issue of unlisted performance options under Equity Incentive Plan". Read the announcement.
Appendix 3G
The attached "Appendix 3G: Notification of issue, conversion or payment up of equity +securities" was released to market. View Appendix 3G.
CEO Bob Proulx Featured on Biotech2050 Podcast
Earlier this year Imagion Biosystems CEO Bob Proulx was invited to be a guest and record an episode of the Biotech2050 podcast. The COVID-19 pandemic delayed…
Vesting of Performance Rights and Appendix 2A
Imagion Biosystems has today advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO, Bob…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
Imagion Biosystems gives notice that, on 4 September 2020 the Company issued 2,514,666 fully paid ordinary shares (Shares) in the Company as the result of…
IBX Secures Additional Capital — Shareholders Exercise Options
Imagion Biosystems announce that it has received a total of $82,939.98 for the exercise of Listed Options. Comprised of $64,189.98 for 2,139,666 Listed…